Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
MacLeod S, Musich S, Keown K, Yeh CS. Practical technological solutions to support successful aging. J Aging Geriatr Med. 2019 Aug 14;3(1).
MacLeod S, Musich S, Ruiz JM, Yeh CS. Perceptions of aging and their impact on older adults' health outcomes. J Aging Geriatr Med. 2019 Apr 30;3(1).
MacLeod S, Musich S, Parikh RB, Hawkins K, Keown K, Yeh CS. Examining approaches to address loneliness and social isolation among older adults. J Aging Geriatr Med. 2018 Feb 8;2(1). doi: 10.4172/2576-3946.1000115
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.